Nuclear factor-kappa B inhibitors; A patent review (2006 - 2010)

Expert Opinion on Therapeutic Patents

Volumn 21, Issue 12, 2011, Pages 1897-1910

  Kwak, Jae Hwan ^a   Jung, Jae Kyung ^a   Lee, Heesoon ^a  

^a Chungbuk National University   (South Korea)

Author keywords

Antitumor effects; immune responses; NF B

Indexed keywords

2 [4 [(4 AMINO 2 METHYLPHENYL)DIAZENYL]PHENYLSULPHENYLSULFONYL]ETHYL HYDROGEN SULFATE; 6 HYDROXY 7 METHOXY N PHENYLCHROMAN 2 CARBOXAMIDE; 7 HYDROXY 6 METHOXY 1,2,3,4 TETRAHYDROISOQUINOLINE DERIVATIVE; AMINOACRIDINE; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; BETA GLUCAN; BORTEZOMIB; CAMPTOTHECIN; DEHYDROXYMETHYLEPOXYQUINOMICIN; DOXORUBICIN; ESTRADIOL; I KAPPA B; IMIDAZOLINE DERIVATIVE; INDAZOLE DERIVATIVE; IRINOTECAN; KL 1156; MELPHALAN; MITOXANTRONE; MYRICERIC ACID A; PARTHENOLIDE; PR 39; PYRIMIDINE DERIVATIVE; RALOXIFENE; SALAZOSULFAPYRIDINE; TETRAHYDROISOQUINOLINE DERIVATIVE; THIAZOLE DERIVATIVE; THIENOPYRIMIDINE DERIVATIVE; TRITERPENE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; W 02;

APOPTOSIS; AUTOIMMUNE DISEASE; CARDIOVASCULAR DISEASE; CELL STRAIN HEK293; COMPARATIVE EFFECTIVENESS; DIABETES MELLITUS; DOSE RESPONSE; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; HELA CELL; HEMATOLOGIC MALIGNANCY; HUMAN; IC 50; INFECTION; INFLAMMATION; MULTIPLE MYELOMA; NEOPLASM; NONHUMAN; OXIDATIVE STRESS; PATENT; PROTEIN DNA BINDING; PROTEIN PHOSPHORYLATION; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DRUG DESIGN; HUMANS; MOLECULAR STRUCTURE; NF-KAPPA B; PATENTS AS TOPIC; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 81855199748     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2011.638285     Document Type: Review

References (99)

1. Sen R, Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 1986;46:705-16
2. Beg AA, Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 1996;274:782-4
3. Kumar A, Takada Y, Boriek AM, et al. Nuclear factor-kappaB: its role in health and disease. J Mol Med 2004;82:434-48
4. Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NF-kappa B. Annu Rev Cell Biol 1994;10:405-55
5. Chen FE, Huang DB, Chen YQ, et al. Crystal structure ofp50/p65 heterodimer of transcription factor NF-kappaB bound to DNA. Nature 1998;391:410-13
6. Lin L, Ghosh S. A glycine-rich region in NF-kappaB p105 functions as a processing signal for the generation of the p50 subunit. Mol Cell Biol 1996;16:2248-54
7. Arenzana-Seisdedos F, Turpin P, Rodriguez M, et al. Nuclear localization of I kappa B alpha promotes active transport of NF-kappa B from the nucleus to the cytoplasm. J Cell Sci 1997;110(Pt 3):369-78
8. Sachdev S, Hoffmann A, Hannink M. Nuclear localization of IkappaB alpha is mediated by the second ankyrin repeat: the IkappaB alpha ankyrin repeats define a novel class of cis-acting nuclear import sequences. Mol Cell Biol 1998;18:2524-34
9. Sachdev S, Bagchi S, Zhang DD, et al. Nuclear import of IkappaBalpha is accomplished by a ran-independent transport pathway. Mol Cell Biol 2000;20:1571-82
10. Malek S, Chen Y, Huxford T, et al. IkappaBbeta, but not IkappaBalpha, functions as a classical cytoplasmic inhibitor of NF-kappaB dimers by masking both NF-kappaB nuclear localization sequences in resting cells. J Biol Chem 2001;276:45225-35
11. RothwarfDM, Zandi E, Natoli G, et al. IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex. Nature 1998;395:297-300
12. Zandi E, RothwarfDM, Delhase M, et al. The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. Cell 1997;91:243-52
13. May MJ, Ghosh S. Signal transduction through NF-kappa B. Immunol Today 1998;19:80-8
14. Baeuerle PA, Baltimore D. NF-kappa B: ten years after. Cell 1996;87:13-20
15. Ahn KS, Aggarwal BB. Transcription factor NF-kappaB: a sensor for smoke and stress signals. Ann NY Acad Sci 2005;1056:218-33
16. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 2000;18:621-63
17. Schmitz ML, Mattioli I, Buss H, et al. NF-kappaB: a multifaceted transcription factor regulated at several levels. Chem Bio Chem 2004;5:1348-58
18. Chen LF, Greene WC. Regulation of distinct biological activities of the NF-kappaB transcription factor complex by acetylation. J Mol Med 2003;81:549-57
19. Pomerantz JL, Baltimore D. Two pathways to NF-kappaB. Mol Cell 2002;10:693-5
20. Xiao G, Harhaj EW, Sun SC. NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100. Mol Cell 2001;7:401-9
21. Ling L, Cao Z, Goeddel DV. NF-kappaB-inducing kinase activates IKK-alpha by phosphorylation of Ser-176. Proc Natl Acad Sci USA 1998;95:3792-7
22. Liang C, Zhang M, Sun SC. beta-TrCP binding and processing of NF-kappaB2/p100 involve its phosphorylation at serines 866 and 870. Cell Signal 2006;18:1309-17
23. Heusch M, Lin L, Geleziunas R, et al. The generation of nfkb2 p52: mechanism and efficiency. Oncogene 1999;18:6201-8
24. Li N, Karin M. Ionizing radiation and short wavelength UV activate NF-kappaB through two distinct mechanisms. Proc Natl Acad Sci USA 1998;95:13012-17
25. Kato T Jr, Delhase M, Hoffmann A, et al. CK2 Is a C-Terminal IkappaB Kinase Responsible for NF-kappaB Activation during the UV Response. Mol Cell 2003;12:829-39
26. Sethi G, Ahn KS, Chaturvedi MM, et al. Epidermal growth factor (EGF) activates nuclear factor-kappaB through IkappaBalpha kinase-independent but EGF receptor-kinase dependent tyrosine 42 phosphorylation of IkappaBalpha. Oncogene 2007;26:7324-32
27. Imbert V, Rupec RA, Livolsi A, et al. Tyrosine phosphorylation of I kappa B-alpha activates NF-kappa B without proteolytic degradation of I kappa B-alpha. Cell 1996;86:787-98
28. Takada Y, Mukhopadhyay A, Kundu GC, et al. Hydrogen peroxide activates NF-kappa B through tyrosine phosphorylation of I kappa B alpha and serine phosphorylation ofp65: evidence for the involvement of I kappa B alpha kinase and Syk protein-tyrosine kinase. J Biol Chem 2003;278:24233-41
29. Chew J, Biswas S, Shreeram S, et al. WIP1 phosphatase is a negative regulator of NF-kappaB signalling. Nat Cell Biol 2009;11:659-66
30. Hur GM, Lewis J, Yang Q, et al. The death domain kinase RIP has an essential role in DNA damage-induced NF-kappa B activation. Genes Dev 2003;17:873-82
31. Janssens S, Tschopp J. Signals from within: the DNA-damage-induced NF-kappaB response. Cell Death Differ 2006;13:773-84
32. Hayden MS, West AP, Ghosh S. NF-kappaB and the immune response. Oncogene 2006;25:6758-80
33. Miagkov AV, Kovalenko DV, Brown CE, et al. NF-kappaB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc Natl Acad Sci USA 1998;95:13859-64
34. Makarov SS. NF-kappa B in rheumatoid arthritis: a pivotal regulator of inflammation, hyperplasia, and tissue destruction. Arthritis Res 2001;3:200-6
35. Marok R, Winyard PG, Coumbe A, et al. Activation of the transcription factor nuclear factor-kappaB in human inflamed synovial tissue. Arthritis Rheum 1996;39:583-91
36. Podolsky DK. Inflammatory bowel disease (1). N Engl J Med 1991;325:928-37
37. Podolsky DK. Inflammatory bowel disease (2). N Engl J Med 1991;325:1008-16
38. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest 2001;107:135-42
39. Eizirik DL, Mandrup-Poulsen T. A choice of death-the signal-transduction of immune-mediated beta-cell apoptosis. Diabetologia 2001;44:2115-33
40. Flores N, Duran C, Blasco MR, et al. NFkappaB and AP-1 DNA binding activity in patients with multiple sclerosis. J Neuroimmunol 2003;135:141-7
41. Oikonomidou O, Vlachoyiannopoulos PG, Kominakis A, et al. Glucocorticoid receptor, nuclear factor kappaB, activator protein-1 and C-jun N-terminal kinase in systemic lupus erythematosus patients. Neuroimmunomodulation 2006;13:194-204
42. Johansen C, Flindt E, Kragballe K, et al. Inverse regulation of the nuclear factor-kappaB binding to the p53 and interleukin-8 kappaB response elements in lesional psoriatic skin. J Invest Dermatol 2005;124:1284-92
43. Breccia M, Alimena G. NF-kappaB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia. Expert Opin Ther Targets 2010;14:1157-76
44. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006;441:431-6
45. Uetsuka H, Haisa M, Kimura M, et al. Inhibition of inducible NF-kappaB activity reduces chemoresistance to 5-fluorouracil in human stomach cancer cell line. Exp Cell Res 2003;289:27-35
46. Huang Z. Bcl-2 family proteins as targets for anticancer drug design. Oncogene 2000;19:6627-31
47. Werner AB, de Vries E, Tait SW, et al. Bcl-2 family member Bfl-1/A1 sequesters truncated bid to inhibit is collaboration with pro-apoptotic Bak or Bax. J Biol Chem 2002;277:22781-8
48. Lopez-Guerra M, Roue G, Perez-Galan P, et al. p65 activity and ZAP-70 status predict the sensitivity of chronic lymphocytic leukemia cells to the selective IkappaB kinase inhibitor BMS-345541. Clin Cancer Res 2009;15:2767-76
49. Hertlein E, Byrd JC. Signalling to drug resistance in CLL. Best Pract Res Clin Haematol 2010;23:121-31
50. Brandt S, Kwok T, Hartig R, et al. NF-kappaB activation and potentiation of proinflammatory responses by the Helicobacter pylori CagA protein. Proc Natl Acad Sci USA 2005;102:9300-5
51. Maeda S, Yoshida H, Ogura K, et al. H. pylori activates NF-kappaB through a signaling pathway involving IkappaB kinases, NF-kappaB-inducing kinase, TRAF2, and TRAF6 in gastric cancer cells. Gastroenterology 2000;119:97-108
52. Bharti AC, Aggarwal BB. Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem Pharmacol 2002;64:883-8
53. Giri DK, Aggarwal BB. Constitutive activation of NF-kappaB causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells. Autocrine role of tumor necrosis factor and reactive oxygen intermediates. J Biol Chem 1998;273:14008-14
54. Rath PC, Aggarwal BB. Antiproliferative effects of IFN-alpha correlate with the downregulation of nuclear factor-kappa B in human Burkitt lymphoma Daudi cells. J Interferon Cytokine Res 2001;21:523-8
55. Younes A, Garg A, Aggarwal BB. Nuclear transcription factor-kappaB in Hodgkin's disease. Leuk Lymphoma 2003;44:929-35
56. Chen F, Castranova V, Shi X. New insights into the role of nuclear factor-kappaB in cell growth regulation. Am J Pathol 2001;159:387-97
57. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I (kappa)B kinase-beta. Nature 1998;396:77-80
58. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 2001;107:241-6
59. Lee JY, Kim JS, Kim JM, et al. Simvastatin inhibits NF-kappaB signaling in intestinal epithelial cells and ameliorates acute murine colitis. Int Immunopharmacol 2007;7:241-8
60. Olivier S, Close P, Castermans E, et al. Raloxifene-induced myeloma cell apoptosis: a study of nuclear factor-kappaB inhibition and gene expression signature. Mol Pharmacol 2006;69:1615-23
61. Schwartz R, Davidson T. Pharmacology, pharmacokinetics, and practical applications of bortezomib. Oncology (Williston Park) 2004;18:14-21
62. Wahl C, Liptay S, Adler G, et al. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 1998;101:1163-74
63. Weber CK, Liptay S, Wirth T, et al. Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology 2000;119:1209-18 University ofSouthampton. GB2421947; 2006
64. Je Il Pharmaceutical Co. WO2007102679; 2007
65. Lull C, Wichers HJ, Savelkoul HF. Antiinflammatory and immunomodulating properties of fungal metabolites. Mediators Inflamm 2005;2005:63-80
66. Luhm J, Langenkamp U, Hensel J, et al. Beta-(1->3)-D-glucan modulates DNA binding of nuclear factors kappaB, AT and IL-6 leading to an anti-inflammatory shift of the IL-1beta/IL-1 receptor antagonist ratio. BMC Immunol 2006;7:5
67. Hypha Holdings Pte Ltd. WO2009017463; 2009
68. Henrich et al. WO2010033958; 2010
69. Agerberth B, Gunne H, Odeberg J, et al. PR-39, a proline-rich peptide antibiotic from pig, and FALL-39, a tentative human counterpart. Vet Immunol Immunopathol 1996;54:127-31
70. Li J, Post M, Volk R, et al. PR39, a peptide regulator of angiogenesis. Nat Med 2000;6:49-55
71. Gao Y, Lecker S, Post MJ, et al. Inhibition of ubiquitin-proteasome pathway-mediated I kappa B alpha degradation by a naturally occurring antibacterial peptide. J Clin Invest 2000;106:439-48
72. The board of regents of the university of texas system. US20090068736; 2009
73. Sc Ag. US20060069102; 2006
74. Sc Ag. WO2007104558; 2007
75. University of Ulsan Foundation for Industry Cooperation. WO2008069632; 2008
76. Misigan State University. WO2007133790; 2007
77. Chaicharoenpong C, Kato K, Umezawa K. Synthesis and structure-activity relationship of dehydroxymethylepoxyquinomicin analogues as inhibitors of NF-kappaB functions. Bioorg Med Chem 2002;10:3933-9
78. Ariga A, Namekawa J, Matsumoto N, et al. Inhibition of tumor necrosis factor-alpha -induced nuclear translocation and activation of NF-kappa B by dehydroxymethylepoxyquinomicin. J Biol Chem 2002;277:24625-30
79. Profectus Biosciences. WO2010148042; 2010
80. Profectus Biosciences. WO2010127058; 2010
81. Profectus Biosciences. WO2010111460; 2010
82. Kim BH, Reddy AM, Lee KH, et al. Inhibitory mechanism of chroman compound on LPS-induced nitric oxide production and nuclear factor-kappaB activation. Biochem Biophys Res Commun 2004;325:223-8
83. Chungbuk National University, Industry-Academy Cooperation Foundation. KR784850; 2007
84. Chungbuk National University, Industry-Academy Cooperation Foundation. KR2010044509; 2010
85. Rho et al. WO2010041827; 2010
86. Savipu Pharmaceuticals. US20080187608; 2008
87. Savipu Pharmaceuticals. WO2007103727; 2007
88. Savipu Pharmaceuticals. WO20070208079; 2007
89. Kurebayashi S, Miyashita Y, Hirose T, et al. Characterization of mechanisms of interleukin-6 gene repression by estrogen receptor. J Steroid Biochem Mol Biol 1997;60:11-17
90. Malnick SD, Shaer A, Soreq H, et al. Estrogen-induced creatine kinase in the reproductive system of the immature female rat. Endocrinology 1983;113:1907-9
91. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. J Am Med Assoc 1998;280:605-13
92. Wyeth. WO2006050006; 2006
93. Prives C, Hall PA. The p53 pathway. J Pathol 1999;187:112-26
94. Rasmussen MK, Iversen L, Johansen C, et al. IL-8 and p53 are inversely regulated through JNK, p38 and NF-kappaB p65 in HepG2 cells during an inflammatory response. Inflamm Res 2008;57:329-39
95. Cleveland Clinic Foundation. WO2006012419; 2006
96. Sudarsanam et al. US20090306073; 2009
97. Merfort I. Patented inhibitors (2002 - 2005) of the transcription factor NF-kappaB. Expert Opin Ther Patent 2006;16:797-810
98. Manning G, Whyte DB, Martinez R et al. The protein kinase complement of the human genome. Science 2002;298:1912-34
99. Traxler P, Furet P. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. Pharmacol Ther 1999;82:195-206